Cyclosporine Or Derivative Utilizing Patents (Class 514/20.5)
  • Patent number: 10188692
    Abstract: The disclosure generally describes methods of preventing or treating ophthalmic diseases or conditions in a mammalian subject, such as diabetic retinopathy, cataracts, retinitis pigmentosa, glaucoma, macular degeneration, choroidal neovascularization, retinal degeneration, and oxygen-induced retinopathy. The methods comprise administering an effective amount of an aromatic-cationic peptide to subjects in need thereof.
    Type: Grant
    Filed: January 9, 2017
    Date of Patent: January 29, 2019
    Assignee: Stealth Biotherapeutics Corp
    Inventors: Liping Liu, Shibo Tang, Xiaoling Liang
  • Patent number: 10065992
    Abstract: Disclosed herein are novel analogs of cyclosporin, pharmaceutical compositions containing them, and methods for their use in the treatment of dry eye and other conditions.
    Type: Grant
    Filed: October 11, 2016
    Date of Patent: September 4, 2018
    Assignee: Allergan, Inc.
    Inventors: Catherine Simone Victoire Frydrych, William Robert Carling, Michael E. Garst, Michael E. Stern, Christopher S. Schaumburg
  • Patent number: 10016376
    Abstract: Provided is a composition for alleviating nephrotoxicity caused by an immunosuppressive drug, including metformin, and a composition for preventing or treating an immune disease, including the same. Further, the composition provided can be useful in improving a treatment effect on diseases requiring immunosuppression by effectively alleviating a decline in renal function caused due to side effects of conventional immunosuppressive drugs, and can also be useful in preventing or treating organ transplant rejection, autoimmune diseases, inflammatory diseases and the like since various methods of co-administering a conventional immunosuppressive drug and metformin are suggested to reduce nephrotoxic side effects of conventional immunosuppressive drugs and maximize immunosuppressive or immunomodulatory effects.
    Type: Grant
    Filed: December 18, 2015
    Date of Patent: July 10, 2018
    Assignee: The Catholic University of Korea Industry-Academic Cooperation Foundation
    Inventors: Mi La Cho, Chul Woo Yang, Jong Young Choi, Sung Hwan Park, Min Jung Park, Seon Yeong Lee, Joo Yeon Jhun, Eun Jung Lee, Jae Kyung Kim, Eun Kyung Kim, Sun Woo Lim
  • Patent number: 9889111
    Abstract: The present invention is directed to a pharmaceutical composition comprising a pharmaceutically acceptable carrier and a ?-(arylsulfonyl)alkylnitrile compound, or a pharmaceutically acceptable salt thereof. The present invention is also directed to a method for treating inflammation, inflammatory-related disorders, or pain, by administering an ?-(arylsulfonyl)alkylnitrile compound or a pharmaceutically acceptable salt or solvate thereof to a subject in need thereof.
    Type: Grant
    Filed: October 31, 2016
    Date of Patent: February 13, 2018
    Assignee: OLATEC THERAPEUTICS LLC
    Inventors: Joseph St. Laurent, Gerald S. Jones, David M. Bresse
  • Patent number: 9835616
    Abstract: The present disclosure an in vitro method of assaying the stimulation of a cytokine storm response comprising the steps of: a. co-culturing PBMCs and matched differentiated endothelial cells to provide a system representative of human responses in vivo, and b. exposing the co-cultured cell system to a test agent, c. analyzing the system for the presence of one or more cytokines released after exposing the co-culture system to said test agent, and d. optionally evaluating the response to the test agent in comparison to a response to one or more control agents.
    Type: Grant
    Filed: March 21, 2014
    Date of Patent: December 5, 2017
    Assignee: Imperial Innovations Ltd.
    Inventor: Jane Alison Mitchell
  • Patent number: 9714271
    Abstract: Analogs of cyclosporin-A are disclosed comprising modifications of the substituents as the positions of amino acids 1 and 3, according to the following Formula. The disclosed compounds include compounds having affinity for cyclophilin, including cyclophilin-A, and reduced immunosuppressivity in comparison with cyclosporin-A and analogs thereof modified solely at position 1.
    Type: Grant
    Filed: October 30, 2015
    Date of Patent: July 25, 2017
    Assignee: ContraVir Pharmaceuticals, Inc.
    Inventors: Alexander Hegmans, Bruce W. Fenske, Dan J. Trepanier, Mark D. Abel, Daren R. Ure, Shin Sugiyama
  • Patent number: 9676696
    Abstract: Personal care compositions containing an active selected from the group consisting of phlorogine, phlorgine BG, deoxyArbutin, sucrose dilaurate, bakuchiol, pyrenoine, millet, arlatone dioic acid, cinnamic acid, ferulic acid, achromaxyl, methyl nicotinamide, oil soluble licorice extract, folic acid, undecylenic acid, zinc undecylenate, L-tryptophan, thiamine HCl, hexylresorcinol, lipidami red vine, dragosine, methyl gentisate, inositol, symdiol 68, laminaine, their salts, their derivatives, their precursors, and/or combinations thereof. Methods for regulating the condition of mammalian keratinous tissue by topically applying the personal care compositions are also provided.
    Type: Grant
    Filed: January 25, 2010
    Date of Patent: June 13, 2017
    Assignee: The Procter & Gamble Company
    Inventor: Tomohiro Hakozaki
  • Patent number: 9561178
    Abstract: Disclosed herein are therapeutic methods, compositions, and medicaments related to cyclosporine.
    Type: Grant
    Filed: July 20, 2007
    Date of Patent: February 7, 2017
    Assignee: Allergan, Inc.
    Inventors: Richard S. Graham, Walter L. Tien, Mayssa Attar, Rhett Schiffman, Aileen Morgan
  • Patent number: 9493511
    Abstract: Disclosed herein are novel analogs of cyclosporin, pharmaceutical compositions containing them, and methods for their use in the treatment of dry eye and other conditions.
    Type: Grant
    Filed: November 6, 2014
    Date of Patent: November 15, 2016
    Assignee: Allergan, Inc.
    Inventors: Catherine Simone Victoire Frydrych, William Robert Carling, Michael E. Garst, Michael E. Stern, Christopher S. Schaumburg
  • Patent number: 9248191
    Abstract: Methods of treating an eye of a human or animal include administering to an eye of a human or animal a composition in the form of an emulsion including water, a hydrophobic component and a cyclosporin component in a therapeutically effective amount of less than 0.1% by weight of the composition. The weight ratio of the cyclosporin component to the hydrophobic component is less than 0.8.
    Type: Grant
    Filed: March 21, 2014
    Date of Patent: February 2, 2016
    Assignee: Allergan, Inc.
    Inventors: Andrew Acheampong, Diane D. Tang-Liu, James N. Chang, David F. Power
  • Patent number: 9101550
    Abstract: The present invention is directed to compositions and methods for stimulating the growth of nails and cuticles in a mammal, including humans. The compositions may be administered topically to the nail bed, nail matrix and cuticle in an amount effective to increase nail growth and thicken, strengthen and smooth the nail. The composition is also effective in strengthening and growing nails, including fingernails and toenails.
    Type: Grant
    Filed: January 22, 2013
    Date of Patent: August 11, 2015
    Assignee: Allergan, Inc.
    Inventors: Scott M. Whitcup, Rhett M. Schiffman, John G. Walt, Debbie D. Mullins, Connie M. Stucker
  • Patent number: 9044394
    Abstract: A composition for increasing the bioavailability of an active pharmaceutical ingredient (“API”) in humans and animals, comprising a first water soluble surfactant having a cloud point greater than about 37° C., a second water soluble surfactant having a cloud point greater than about 37° C., wherein a mixture of the first surfactant and the second surfactant comprises a cloud point less than about 37° C.
    Type: Grant
    Filed: November 30, 2011
    Date of Patent: June 2, 2015
    Assignee: PruGen IP Holdings, Inc.
    Inventor: Bhiku G. Patel
  • Publication number: 20150148299
    Abstract: Provided herein include formulations for topical administration, such as ophthalmic formulations, and methods of using such formulations. In some aspects and embodiments the formulations may include a polyoxyl lipid or fatty acid, and or a polyalkoxylated alcohol and may include nanomicelles. Also include methods of treating or preventing diseases or conditions, such as ocular diseases or conditions.
    Type: Application
    Filed: February 2, 2015
    Publication date: May 28, 2015
    Inventors: Ashim K. Mitra, Sidney L. Weiss
  • Patent number: 9040487
    Abstract: The present invention relates to a cyclosporine emulsion containing: i) a cyclosporine ii) a natural oil (long chain triglyceride) iii) a phosphatidylcholine, iv) glycerol, v) a pharmaceutically tolerable alkali salt of a free fatty acid, vi) a medium chain triglyceride-oil vii) optionally, hydrochloric acid or sodium hydroxide for pH adjustment viii) water.
    Type: Grant
    Filed: September 30, 2011
    Date of Patent: May 26, 2015
    Assignee: NEUROVIVE PHARMACEUTICAL AB
    Inventor: Eskil Elmér
  • Publication number: 20150132369
    Abstract: A liposomal formulation for targeting immunotherapy, with synergistic effect in the case of encapsulating an immunosuppressive drug, such as Cyclosporine A, and the method of preparing the same. The reduced toxicity and significant reduction of Delayed-Type Hypersensitivity DTH) due to extremely reduced dosage, potential therapeutic value in control of chronic transplant rejection, allergies and certain autoimmune diseases, and increased efficacy are some of numerous and significant benefits of the present invention.
    Type: Application
    Filed: November 9, 2014
    Publication date: May 14, 2015
    Applicant: Exir Nano Sina Company
    Inventors: S. Mahdi Rezayat, Alireza Partoazar, Kambiz Gilani
  • Publication number: 20150133391
    Abstract: Methods, devices, compositions and kits are provided for analysis of the microbiome or individual components thereof in an individual. The methods find use in a determination of infection, in analysis of the microbiome structure, in determining the immunocompetence of an individual, and the like. In some embodiments of the invention, the individual is treated with a therapeutic regimen, e.g. drugs, diet, radiation therapy, and the like.
    Type: Application
    Filed: November 7, 2014
    Publication date: May 14, 2015
    Inventors: Iwijn de Vlaminick, Michael Kertesz, Kiran Kaur Khush, Mark Alec Kowarsky, Lance Martin, Stephen R. Quake, Hannah Valantine
  • Publication number: 20150132396
    Abstract: The present invention relates to a formulation comprising a pharmaceutically active ingredient and a coating. The invention also relates to the use of the formulation in the treatment and prevention of disorders of the gastrointestinal tract. Also disclosed are methods for preparing the formulations.
    Type: Application
    Filed: November 7, 2014
    Publication date: May 14, 2015
    Applicant: SIGMOID PHARMA LIMITED
    Inventors: Ivan Coulter, Vincenzo Aversa, Mónica Rosa, Bernard Francis McDonald
  • Publication number: 20150132374
    Abstract: A modified release composition comprising cyclosporin A for oral administration. The composition may comprise a core and a modified release coating, wherein the core comprises a hydrogel-forming polymer matrix and cyclosporin A. The composition may be in the form of a minibead. The compositions provide a pharmacokinetic profile and dissolution profile which provides release of cyclosporin A in the lower GI tract whilst minimising systemic exposure. Also disclosed are uses of the composition in the treatment of conditions affecting the lower GI tract, particularly the colon.
    Type: Application
    Filed: November 7, 2014
    Publication date: May 14, 2015
    Applicant: SIGMOID PHARMA LIMITED
    Inventors: Ivan Coulter, Vincenzo Aversa, Mónica Rosa
  • Publication number: 20150133378
    Abstract: A method for identifying a kidney transplant recipient at an increased risk of developing interstitial fibrosis or tubular atrophy which comprises obtaining a post-transplant urine sample from the kidney transplant recipient; measuring the level of clusterin in the urine sample; comparing the level of clusterin in the patient sample to the level of clusterin in a control sample from the urine of a non-fibrotic kidney transplant recipient; diagnosing a kidney transplant recipient with a clusterin level that is significantly higher than the clusterin level in the control as being at an increased risk of developing interstitial fibrosis or tubular atrophy.
    Type: Application
    Filed: April 17, 2013
    Publication date: May 14, 2015
    Inventors: Barbara Murphy, Philip J. O'Connell
  • Publication number: 20150132260
    Abstract: The present invention relates to the use of the measure of anelloviral load for the determination of immunosuppression. More precisely, the present invention provides a method for characterizing the immunosuppressed or non-immunosuppressed status of a subject, comprising the steps of determining the anelloviral load from a biological sample of the said subject, and determining from the said comparison the immunosuppressed or non-immunosuppressed status. The determination of the immunosuppressed status of the subject can then be used to design or adapt a therapeutic treatment.
    Type: Application
    Filed: April 19, 2013
    Publication date: May 14, 2015
    Inventors: Marc Eloit, Justine Cheval, Charles Hebert, Marc Lecuit
  • Publication number: 20150133390
    Abstract: Methods for identifying new therapeutic activities for known therapeutic agents, as well as systems for practicing the same, are provided. Aspects of the invention further include are methods and compositions for the treatment of an acute graft rejection (AR).
    Type: Application
    Filed: January 25, 2013
    Publication date: May 14, 2015
    Applicant: National Institutes of Health (NIH), U.S. Dept. of Health and Human Services (DHHS), U.S. Govt.
    Inventors: Purvesh Khatri, Atul J. Butte, Minnie M. Sarwal
  • Publication number: 20150125494
    Abstract: Provided is an ophthalmic composition containing cyclosporine as an active ingredient and including polyethoxylated castor oil or polyethoxylated hydrogenated castor oil, and a method of preparing the same. Particularly, the ophthalmic composition is prepared as a nanoemulsion having a particle diameter of 100 nm or less simply by mixing and stirring an oil phase and an aqueous phase without using a high speed stirring or shearing machine, so that it is very physiochemically stable and storable for a long time. In addition, the ophthalmic composition causes no irritation to eyes.
    Type: Application
    Filed: January 22, 2013
    Publication date: May 7, 2015
    Inventors: Sung Joon Wang, Kwang Ho Cha, Han Kang, Bo Kyung Sun
  • Publication number: 20150118209
    Abstract: Described herein are methods for treating and preventing graft versus host disease using ACK inhibitors. The methods include administering to an individual in need thereof an ACK inhibitor such as ibrutinib for treating and preventing graft versus host disease.
    Type: Application
    Filed: October 24, 2014
    Publication date: April 30, 2015
    Inventors: John C. BYRD, Jason A. DUBOVSKY, Natarajan MUTHUSAMY, Amy Jo JOHNSON, David MIKLOS
  • Publication number: 20150118229
    Abstract: The invention relates to the use of a JAK1 kinase-selective inhibitor that has minimal inhibitory activity towards Jak2 kinase for treating a disease, such as an inflammatory disease (e.g., moderate to severe Rheumatoid Arthritis) and/or bone loss, either alone or in combination with a DMARD (disease modifying anti-rheumatic drug), such as methotrexate. The invention also provides pharmaceutical composition, dosage formulation, administration route, and dosage schedule thereof.
    Type: Application
    Filed: October 24, 2014
    Publication date: April 30, 2015
    Applicant: ABBVIE INC.
    Inventors: Jeffrey W. Voss, Heidi S. Camp, Robert J. Padley
  • Publication number: 20150111833
    Abstract: Methods and compositions are provided for treating an ocular disease in a subject in need thereof by increasing the bioavailability of a drug in the subjects eye. By one approach, the ocular disease is endophthalmitis. The methods and compositions provided herein include an efflux transporter inhibitor and a drug effective for treating the ocular disease. The efflux transporter inhibitor is effective to reduce the efflux of the drug through at least one of Pglycoprotein (Pgp), breast cancer resistant protein (BCRP), and multidrug resistant associated protein 19 (MRP19). In one aspect, cyclosporine A is the efflux transporter inhibitor.
    Type: Application
    Filed: March 15, 2013
    Publication date: April 23, 2015
    Inventors: Pradeep K. Karla, Harpal S. Mangat
  • Publication number: 20150111815
    Abstract: The present invention relates to a compound of formula (I): or pharmaceutically acceptable salt thereof, wherein the symbols are as defined in the specification; a pharmaceutical composition comprising the same; a method for treating or preventing a viral infection using the same.
    Type: Application
    Filed: October 24, 2014
    Publication date: April 23, 2015
    Inventors: Zhuang SU, Zhengyu LONG, Zhennian HUANG, Suizhou YANG
  • Patent number: 8999938
    Abstract: The ophthalmic drug delivery vehicles provide comfort and compliance; drug solubility, residence time and permeability; and reduce side effects. In addition, the delivery vehicle can be slightly modified to provide an artificial tear formulation.
    Type: Grant
    Filed: June 21, 2013
    Date of Patent: April 7, 2015
    Assignee: GNT LLC
    Inventor: Gerald Horn
  • Patent number: 8993625
    Abstract: A method of parenterally administering a composition, the method including parenterally administering to a person a composition including at least one omega-3 fatty acid and at least one drug, wherein the at least one omega-3 fatty acid source and the at least one drug are administered simultaneously.
    Type: Grant
    Filed: September 12, 2011
    Date of Patent: March 31, 2015
    Assignee: Stable Solutions LLC
    Inventor: David F. Driscoll
  • Publication number: 20150079191
    Abstract: A cured non-polymeric gel including a plurality of non-polymeric cross-links. The non-polymeric cross-links result from curing an oil or oil composition at selected curing conditions to achieve a desired amount of cross-linking to form the non-polymeric get. The desired amount of cross-linking is selected based on a desired rate of degradation of the gel after the gel is implanted. The oil or oil composition comprises one or more of eicosapentaenoic acid (EPA), docosahexaenoic acid (DHA), or alphalinolenic acid (ALA).
    Type: Application
    Filed: October 10, 2014
    Publication date: March 19, 2015
    Applicant: ATRIUM MEDICAL CORPORATION
    Inventors: Roger LABRECQUE, Philip MCNAMARA, Joseph FERRARO, Lisa ROGERS, Paul MARTAKOS, Theodore KARWOSKI, Steve A. HERWECK, Keith M. FAUCHER, Thomas M. SWANICK
  • Publication number: 20150079116
    Abstract: NK cell licensing predisposes patients to chronic inflammatory disease. Methods and kits to diagnose and treat chronic inflammatory disease based on genetic haplotype and cytokine profile are described herein.
    Type: Application
    Filed: April 11, 2013
    Publication date: March 19, 2015
    Inventors: Jonathan Braun, Lin Lin
  • Patent number: 8980839
    Abstract: Provided herein include formulations for topical administration, such as ophthalmic formulations, and methods of using such formulations. In some aspects and embodiments the formulations may include a polyoxyl lipid or fatty acid, and or a polyalkoxylated alcohol and may include nanomicelles. Also include methods of treating or preventing diseases or conditions, such as ocular diseases or conditions.
    Type: Grant
    Filed: August 23, 2013
    Date of Patent: March 17, 2015
    Assignee: Ocular Technologies SARL
    Inventors: Ashim K. Mitra, Sidney L. Weiss
  • Publication number: 20150072938
    Abstract: A cationic graft-copolymer for a drug delivery system comprising a unit derived from a having a hydroxyl groups, namely, a cationic polysaccharide of the following formula (1) (C6H7O2(OH)3-a (OX)a)xH2O (1) and a unit derived from a polymerizable olefin compound of the following formula (2) (a, x, X, R4, R5, R6, and R7 are defined in claim 1-8); a process for preparing the same and a transfection reagent made therefrom.
    Type: Application
    Filed: February 21, 2013
    Publication date: March 12, 2015
    Inventor: Yasuhiko ONISHI
  • Publication number: 20150071874
    Abstract: Methods and compositions containing a phorbol ester or a derivative of a phorbol ester are provided for the treatment of chronic and acute conditions. Such conditions may be caused by disease, be symptoms or sequelae of disease. Chronic and acute conditions may be due to viral infections such as HIV and AIDS, neoplastic diseases stroke, kidney disease, urinary incontinence, autoimmune disorders, Parkinson's disease, prostate hypertrophy, aging, or the treatment of such diseases. Additional compositions and methods are provided which employ a phorbol ester or derivative compound in combination with at least one additional agent to yield more effective treatment tools against acute and chronic conditions in mammalian subjects.
    Type: Application
    Filed: September 12, 2013
    Publication date: March 12, 2015
    Applicant: Biosuccess Biotech Co. Ltd.
    Inventors: Zheng Tao Han, Hung-Fong Chen
  • Publication number: 20150065433
    Abstract: Disclosed herein are novel analogs of cyclosporin, pharmaceutical compositions containing them, and methods for their use in the treatment of dry eye and other conditions.
    Type: Application
    Filed: November 6, 2014
    Publication date: March 5, 2015
    Applicant: ALLERGAN, INC.
    Inventors: Catherine Simone Victoire Frydrych, William Robert Carling, Michael E. Garst, Michael E. Stern, Christopher S. Schaumburg
  • Patent number: 8969306
    Abstract: A composition comprising a therapeutically effective amount of cyclosporin A, a blend of oils having a specific gravity of from 0.90 to 1.07, and a surfactant is disclosed herein.
    Type: Grant
    Filed: September 13, 2013
    Date of Patent: March 3, 2015
    Assignee: Allergan, Inc.
    Inventors: James N. Chang, Orest Olejnik, Bruce A. Firestone
  • Patent number: 8969305
    Abstract: Described herein is an aqueous ophthalmic solution containing an immunosuppressive agent, such as cyclosporin A, and at least three polymers. The three polymers are preferably a combination of a cellulose derivative, a polyvinyl derivative, and a macrogolglycerol hydroxystearate.
    Type: Grant
    Filed: March 12, 2013
    Date of Patent: March 3, 2015
    Assignee: Laboratories Thea
    Inventors: Emmanuel Muriaux, Fabrice Mercier
  • Patent number: 8969307
    Abstract: A composition comprising from about 0.001% to about 0.4% cyclosporin A, a surfactant, and an oil having a specific gravity from 0.8 to 0.95 is disclosed herein.
    Type: Grant
    Filed: November 4, 2013
    Date of Patent: March 3, 2015
    Assignee: Allergan, Inc.
    Inventors: James N. Chang, Orest Olejnik, Bruce A. Firestone
  • Publication number: 20150056165
    Abstract: The present invention relates to novel cyclosporine analogues having antiviral activity against HCV and useful in the treatment of HCV infections. More particularly, the invention relates to novel cyclosporine analogue compounds, compositions containing such compounds and methods for using the same, as well as processes for making such compounds.
    Type: Application
    Filed: August 26, 2014
    Publication date: February 26, 2015
    Inventors: Yat Sun Or, Guoqiang Wang, Jiang Long, In Jong Kim
  • Publication number: 20150057233
    Abstract: The present invention relates to a calcineurin inhibitor for use in the treatment of a lesional vestibular disorder.
    Type: Application
    Filed: February 22, 2013
    Publication date: February 26, 2015
    Inventor: Jonas Dyhrfjeld-Johnsen
  • Publication number: 20150045309
    Abstract: Disclosed herein is a composition comprising cyclosporin A at a concentration between about 0.001% (w/v) and about 1.0% (w/v), a plant oil at a concentration between about 0.01% (w/v) and about 10% (w/v), and macrogol 15 hydroxystearate at a concentration between about 0.01% (w/v) and about 10% (w/v).
    Type: Application
    Filed: October 27, 2014
    Publication date: February 12, 2015
    Inventors: Aileen Morgan, Anuradha V. Gore, Mayssa Attar
  • Publication number: 20150038404
    Abstract: This invention relates to novel macrocyclic compounds (e.g., those delineated in the formulae herein), pharmaceutically acceptable salts, solvates, and hydrates thereof. This invention also provides compositions comprising a compound of this invention and the use of such compounds and compositions in methods of treating diseases and conditions that are beneficially treated by administering inhibitors of the protease elastase.
    Type: Application
    Filed: February 22, 2013
    Publication date: February 5, 2015
    Inventors: Hendrik Luesch, Valerie J. Paul, Lilibeth A. Salvador
  • Publication number: 20150038431
    Abstract: Provided herein are methods of evaluating efficacy of a treatment in a subject having eye inflammation (e.g., a subject having dry eye syndrome) and selecting a subject for participation in a clinical study. Also provided are methods of treating a subject having eye inflammation (e.g., a subject having dry eye syndrome).
    Type: Application
    Filed: February 21, 2013
    Publication date: February 5, 2015
    Inventors: Pedram Hamrah, Reza Dana, Bernardo Cavalcanti, Andrea Cruzat
  • Publication number: 20150031628
    Abstract: Oral dosage compositions for drugs normally given intravenously such as Paclitaxel, containing a plant sterol to enhance solubility and a small intestine efflux inhibitor to prevent P-glycoprotein from being a barrier to absorption.
    Type: Application
    Filed: August 6, 2014
    Publication date: January 29, 2015
    Inventor: Curtis A. Spilburg
  • Publication number: 20150025020
    Abstract: The present invention relates to a self-preserved oil dispersion. Especially, the present invention relates to a self-preserved oil dispersion including a dispersed oil phase, an aqueous phase and at least one surfactant, wherein said oil dispersion comprises boric acid in an amount ranging from 0.005% to 0.075% in weight of the total weight of the oil dispersion, said amount of boric acid being a preservative effective amount so that the oil dispersion has a preservative activity.
    Type: Application
    Filed: February 22, 2013
    Publication date: January 22, 2015
    Inventors: Jean-Sébastien Garrigue, Frédéric Lallemand, Betty Philips
  • Publication number: 20150011480
    Abstract: Disclosed herein is a method of treating blurred vision, of increasing keratocyte density, of increasing goblet cell density, and of treating psychological distress following surgery on the eye, the method comprising administering a cyclosporin composition to the affected eye of an individual.
    Type: Application
    Filed: September 19, 2014
    Publication date: January 8, 2015
    Inventor: Rhett M. Schiffman
  • Patent number: 8927005
    Abstract: Described herein are liquid formulations which deliver a variety of therapeutic agents, including but not limited to rapamycin, to a subject for an extended period of time; liquid formulations which form a non-dispersed mass when placed in an aqueous medium of a subject; liquid formulations, comprising a therapeutic agent and a plurality of polymers; and methods for delivering therapeutic agents to a subject for an extended period of time using the liquid formulations. The liquid formulation may be placed in an aqueous medium of a subject, including but not limited to via intraocular or periocular administration. A method may be used to administer rapamycin to treat or prevent angiogenesis, choroidal neovascularization, or age-related macular degeneration in a subject.
    Type: Grant
    Filed: January 14, 2013
    Date of Patent: January 6, 2015
    Assignee: Santen Pharmaceutical Co., Ltd.
    Inventors: Sreenivasu Mudumba, Philippe J M Dor, Thierry Nivaggioli, David A. Weber, Sidiq Farooq
  • Publication number: 20140378401
    Abstract: The ophthalmic drug delivery vehicles provide comfort and compliance; drug solubility, residence time and permeability; and reduce side effects. In addition, the delivery vehicle can be slightly modified to provide an artificial tear formulation.
    Type: Application
    Filed: December 18, 2013
    Publication date: December 25, 2014
    Applicant: GNT, LLC
    Inventor: Gerald Horn
  • Publication number: 20140378391
    Abstract: The ophthalmic drug delivery vehicles provide comfort and compliance; drug solubility, residence time and permeability; and reduce side effects. In addition, the delivery vehicle can be slightly modified to provide an artificial tear formulation.
    Type: Application
    Filed: June 21, 2013
    Publication date: December 25, 2014
    Inventor: Gerald Horn
  • Patent number: 8906861
    Abstract: A composition is described herein comprising cyclosporin A, polysorbate 80, a polyoxyethylene stearate, and an oil; wherein the composition is an emulsion which is ophthalmically acceptable. Methods of treating diseases or conditions using said compositions, and medicaments related thereto, are also disclosed herein.
    Type: Grant
    Filed: January 28, 2009
    Date of Patent: December 9, 2014
    Assignee: Allergan, Inc.
    Inventors: Walter L. Tien, Richard S. Graham, James N. Chang
  • Patent number: 8889629
    Abstract: The invention relates to the use of a cyclic undecapeptide, with the structure in formula (I), for the preparation of a medicament for administration during a myocardial ischaemic event.
    Type: Grant
    Filed: January 10, 2006
    Date of Patent: November 18, 2014
    Assignee: Debiopharm International SA
    Inventors: Pietro Scalfaro, Jean-Maurice Dumont, Grégoire Vuagniaux